Objective: To assess the benefits and harms of cannabis-based products for pediatric epilepsy. Methods: We identified in this living systematic review randomized controlled trials (RCTs) and nonrandomized studies (NRSs) involving children with epilepsy treated with cannabis-based products. We searched MEDLINE, Embase, PsycINFO, Cochrane Library, and gray literature (April 25, 2018). The primary outcome was seizure freedom; secondary outcomes were seizure frequency (total, ≥50% reduction), quality of life, sleep, status epilepticus, death, gastrointestinal adverse events, and visits to the emergency room. Data were pooled by randomeffects meta-analysis. Risk of bias was assessed for each study, and GRADE was used to assess the quality of evidence for each outcome. Results: Four RCTs and 19 NRSs were included, primarily involving cannabidiol.
and contributing high costs to the health care system. 5 Although AEDs are the mainstay of treatment, these are often ineffective at reducing seizures and are associated with multiple adverse events. 6 Interest has been steadily growing in the use of cannabis-based treatments for pediatric epilepsy, 7 partly owing to media reports of successful cases. 8 Ninedelta-tetrahydrocannabinol (THC) and cannabidiol (CBD) have received the greatest attention as potential antiepileptic agents. In practice, the psychoactive properties of THC may limit its potential as an antiepileptic treatment, especially in children. In contrast, CBD has little psychoactive effect and, in animal models, is protective against multiple seizure types. 7 However, until recently there had been relatively little clinical research into the effectiveness and safety of cannabis-based treatments for epilepsy, and there are large discrepancies between the beliefs of neurologists and the general public as to whether there is sufficient evidence of effectiveness and safety. 9 A 2014 Cochrane review 10 included four randomized controlled trials (RCTs) that assessed the use of cannabinoids in adults with epilepsy, reporting that no reliable conclusions could be made about its efficacy and safety. 10 However, recent
RCTs and nonrandomized studies (NRSs) have suggested a beneficial effect of CBD in the treatment epilepsy in children, [11] [12] [13] [14] [15] and the US Food and Drug Administration recently approved the first cannabis-based product (Epidiolex; GW Pharmaceuticals), a pharmaceutical-grade cannabidiol extract, for the treatment of Dravet and Lennox-Gastaut syndromes. 16 In the present study, we performed a systematic review to identify studies involving the use of cannabis and cannabis-based products as treatment for pediatric epilepsy. Systematic review methodology provides a lens through which the evidence from various types of studies can be viewed and compared, to assess their quality and applicability to stakeholders (eg, caregivers, clinicians, policymakers). 17 
| Objective and significance
The aim of this study is to provide an up-to-date comprehensive summary of the evidence assessing the use of cannabis-based treatments for epilepsy in children. Because the evidence base is rapidly changing, living systematic review methodology will be used to provide parents, clinicians, and policy makers with up-to-date evidence to inform their decision making.
| MATERIALS AND METHODS
The systematic review protocol was developed using guidance from the PRISMA-P statement, 18 registered in PROS-PERO (CRD42018084755), and published. 19 Two family members (C.A., A.E.R.) of children with epilepsy and a pediatric neurologist (B.M.) with experience caring for children with DRE were involved in protocol development. Screening and data extraction were performed using Distiller SR (Evidence Partners). This report follows the PRISMA guidelines (Appendix S1). 20 
| Eligibility criteria
We included RCTs and NRSs examining the use of cannabis as a treatment for any type of epilepsy in children (≤18 years). Interventions included any type of cannabisbased product, including CBD, cannabinol, THC, or their combinations, administered by any route (eg, oral, inhalation). Eligible comparators included pharmacologic (ie, AEDs) and nonpharmacologic (eg, diet therapy, vagus nerve stimulation, resective brain surgery) treatments, as well as placebo, usual care, or no treatment.
| Outcomes
The outcomes were chosen in consultation with a practicing neurologist (B.M.) and two patient family representatives (C.A., A.E.R. 
| Risk of bias and quality of the evidence
Risk of bias (RoB) was assessed by two reviewers (J.E., D.D.) for each study that reported at least one outcome of interest. For RCTs, bias was assessed by use of the Cochrane Collaboration's RoB tool 22 ; to be considered at overall low RoB, a study must have been at low risk for each of the following domains: allocation concealment, blinding (participants, outcome assessors, investigators) for subjective outcomes, and incomplete outcome data. The potential for bias in NRS was assessed by use of the SIGN50 Checklist (comparative cohort studies), 23 the National Institutes of Health Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group (single-arm cohort studies), 24 and the Joanna-Briggs Institute Checklist for Analytic Cross Sectional Studies. 25 To facilitate comparison across tools, we judged overall RoB according to the most serious risk across all domains, regardless of assessment tool. Two independent reviewers (J.E., V.S.) assessed the quality/certainty of the evidence for each outcome by use of the GRADE method. 26 Disagreements were resolved by discussion.
| Data synthesis
The full analysis plan is available. 19 Descriptive summaries are provided for study selection, study and patient characteristics, and quality assessment. Data from RCTs were pooled by random-effects meta-analyses by use of RevMan Table 2 ). The baseline frequency of total seizures was variable across RCTs ( Table 2) . Of the 19 NRSs, two were comparative cohort studies (one prospective, one retrospective), 31, 35 12 were single-arm cohort studies (eight prospective, four retrospective), [13] [14] [15] 32, 34, 37, 38, [40] [41] [42] [43] [44] four were cross-sectional surveys, 11, 36, 39, 45 and one was a case series 33 (Appendix S5). In total, the NRSs involved 1,115 participants (range = 5-214) with variable baseline seizure frequency, and variable treatment durations (10 days to 57 months). Fourteen NRSs included participants with multiple forms of DRE (Appendix S5), 11, [13] [14] [15] 31, [34] [35] [36] [37] [38] [39] [40] [41] [42] whereas
The types of cannabis-based interventions varied among studies, although more than half involved CBD (68%). Not all interventions were well described, and some included "artisanal" products, 38 products from illicit cannabis suppliers, 39 or homemade extracts. 11 Most cannabis-based products were administered orally, although one study 14 involved use of inhaled cannabis by some participants.
| Risk of bias
All four RCTs were at overall low RoB (Appendix S7); however, selective outcome reporting was a potential concern in three RCTs, 12, 29, 30 with discrepancies noted between the protocol or ClinicalTrials.gov record and the published report. The overall RoB was considered high for all NRSs, owing to at least one of the following: lack of a control group, lack of blinding and subjective outcomes, self-selection or unclear selection of participants, inconsistency in interventions across participants, or a lack of detail about the interventions (Appendix S5). 11, 36, 45 ). Among children with Dravet syndrome who received CBD in one RCT, 12 5% (3/61) experienced freedom from all seizures, whereas no children in the placebo group (n = 59) became seizure-free during a 14-week treatment period (risk difference = 5%, 95% CI = −1% to 11%; low GRADE certainty). Among the NRSs, estimates of seizure freedom ranged from 1% to 20% (pooled proportion = 7%, 95% CI = 4%-11%, duration = 8 weeks to 33 months), with the highest estimates observed among cross-sectional studies (very low certainty; Appendix S9). one cross-sectional study 39 ; Appendix S10). Among the RCTs, the pooled median difference in monthly seizure frequency between CBD and placebo was −19.8% (95% CI = −27.0% to −12.6%; moderate certainty; 14 weeks). Among the NRSs, the reported reduction in total seizures with use of a cannabis-based product was between 30% and 90% (duration = 8 weeks to >16 months; very low certainty).
| Summary of results
Five studies reported the effect of cannabis-based products on the frequency of tonic-clonic seizures (three RCTs, 12, 29, 30 two prospective single-arm cohorts 13, 44 ;
Appendix S11 11, 36 ; Appendix S12).
Among children with Lennox-Gastaut syndrome in one RCT, 37% (23/86) of children randomized to CBD had a 50% or greater reduction in seizure frequency, compared with 21% (18/85) of children randomized to placebo (RR = 1.76, 95% CI = 1.07-2.88; moderate certainty; duration = 14 weeks). 30 Among NRSs, estimates of treatment response ranged from 24% to 100% (duration = 8 weeks to 57 months; very low certainty).
| Quality of life
Five studies (three RCTs, 12, 29, 30 two prospective single-arm cohort studies 13, 46 ) assessed quality of life among children (Appendix S13). In the RCTs, there was no statistically significant difference in overall score on the Quality of Life in Childhood Epilepsy scale between CBD and placebo groups (mean difference = 0.6, 95% CI = −2.6 to 3.9; moderate certainty; duration = 14 weeks). Both single-arm cohort studies reported statistically significant improvements in quality of life relative to the baseline period after treatment with CBD (duration = 12-82 weeks; very low certainty). 32, 37 None of the included studies assessed caregiver quality of life. ; duration = 2 weeks to 57 months), with a higher proportion reported in cross-sectional studies (68%, 95% CI = 46%-90%) compared with retrospective cohort studies (8%, 95% CI = 4%-11%; very low certainty; Appendix S14). Impaired sleep was reported in five NRSs (four prospective cohort studies, 31, 32, 42, 44 one cross-sectional survey 11 ), affecting 4% (95% CI = 0%-7%) of children who received a cannabis-based product (duration = 10 days to 82 weeks; very low certainty).
| Status epilepticus
Status epilepticus was reported in six studies, including three RCTs 12, 29, 30 and three NRSs (two prospective cohort studies, 13, 14 one retrospective cohort study 46 ; Appendix S15). In the RCTs, 12, 29, 30 the RR of status epilepticus was 1.39 (95% CI = 0.55-3.47; low certainty; duration = 14 weeks). Among the NRSs, the pooled prevalence of status epilepticus was 4% (95% CI = 0%-8%; duration = 12 weeks to 33 months; very low certainty).
| Death
Deaths were reported among children who received a cannabis-based product in six studies (one RCT, 30 two prospective cohort studies, 13, 43 three retrospective cohort studies 34, 38, 46 ; Appendix S16); an additional three studies 12, 28, 31 reported that no deaths had occurred during the treatment period). Thiele and colleagues 30 reported the death of one participant with Lennox-Gastaut syndrome who received CBD (20 mg/kg/d; n = 86) during their 14-week RCT; the death was attributed to respiratory failure and deemed by study authors to be unrelated to treatment. No deaths were reported in the placebo group (n = 85; low certainty). An additional six deaths from various causes (including two reports of sudden unexpected death in epilepsy) were reported in five NRS 13, 34, 38, 43, 46 (n = 313; duration = 1-29 months; very low certainty).
| Gastrointestinal adverse events
Diarrhea or vomiting was reported in four RCTs 12,28-30 and nine NRSs (six prospective cohort studies, 13, 14, 31, 32, 43, 44 three cross-sectional studies 11, 36, 45 ; Appendix S17). An additional two NRSs 15, 40 reported gastrointestinal events without specifying the specific adverse events. In the RCTs, the pooled RR was 1.54 (95% CI = 0.92-2.58) for any gastrointestinal adverse event, 1.00 (95% CI = 0.51-1.96) for vomiting, and 2.25 (95% CI = 1.38-3.68) for diarrhea (low certainty; duration = 3 to 14 weeks). Among the NRSs, the pooled proportion of participants who experienced at least one of vomiting or diarrhea was 8% (95% CI = 4%-12%; very low certainty; Appendix S17). A similar proportion of children were reported to have had vomiting (5%, 95% CI = 2%-8%) and diarrhea (7%, 95% CI = 2%-12%). The estimated incidence of both outcomes was highest for prospective cohort studies (vomiting: 7%, 95% CI = 3%-11%; diarrhea: 9%, 95% CI = 3%-16%), whereas estimates were considerably lower for cross-sectional studies (vomiting: 3%, 95% CI = 1%-7%; diarrhea: 2%, 95% CI = 0%-12%; duration = 10 days to 57 months).
| Visits to the emergency room
No studies reported visits to the emergency room during the study period.
3.6 | Sensitivity analyses 3.6.1 | Type of cannabis-based product To date, all RCTs involved oral CBD (5-20 mg/kg/d). Similarly, most of the NRSs (68%) involved CBD. Although some NRSs involved the use of non-CBD-based treatments, such studies typically included use of more than one product of varying composition (Appendix S5), precluding assessment of the effect of individual formulations. Data were insufficient to assess the impact of cannabis strain, level of THC, or THC:CBD ratio.
| Comedications
Two NRSs 35, 42 assessed the effect of concomitant CBD and clobazam. Among children with DRE taking CBD and clobazam, the level of clobazam increased by 60% after 4 weeks of treatment, whereas N-desmethylclobazam levels increased by 500% (n = 13). 42 Nine of these children (69%) experienced ≥50% reduction in seizures from ELLIOTT ET AL.
baseline, with a mean reduction of 51% in seizure frequency; two children (15%) became seizure-free. The authors noted that the observed adverse events were similar to those seen in patients with high clobazam doses (eg, drowsiness) and were alleviated by clobazam dose reduction. 42 A similar proportion of children were reported to have experienced seizure freedom when administered various artisanal CBD products in addition to clobazam (9%); seizure freedom was reported for 14% of children who received CBD alone and 11% who received clobazam alone. 35 A higher proportion of children taking concomitant CBD and clobazam experienced seizure freedom (44%), compared with either alone (CBD: 33%; clobazam: 38%). 35 
| Subgroup analyses
Few studies have assessed cannabis-based treatments in specific epilepsy syndromes, with the exception of four RCTs involving participants with Dravet syndrome 12, 28 or
Lennox-Gastaut syndrome 29, 30 and three NRSs involving participants with TSC, 44 Sturge-Weber syndrome, 32 or febrile infection-related epilepsy. 43 In general, available evidence suggests that CBD reduces seizure frequency across epilepsy syndromes (Appendix S18); however, these findings are predominately based on small open-label studies at high RoB, and no data are available for other cannabisbased products. No data were available to assess the outcomes among different age groups or by sex.
| Ongoing studies
We identified 33 yet-unpublished studies registered in ClinicalTrials.gov, in varying stages of completion (Appendix S19). An additional 34 conference abstracts were identified, of which 14 represent potentially unpublished studies (Appendix S20).
| DISCUSSION
Despite recorded medical use of cannabis dating back to the 2nd century BCE, 47 until recently there had been few clinical studies of its effectiveness and safety, especially among children. However, the past few years have seen a sharp increase in the number of clinical studies involving cannabis for pediatric epilepsy. We undertook this systematic review to provide an up-to-date, comprehensive summary of the available evidence to support decision making by parents, clinicians, and policy makers. The evidence from four recently published high-quality RCTs suggests that CBD probably reduces seizures in children with DRE, without a corresponding increase in seizure freedom or quality of life (moderate to low certainty of evidence). In particular, all of the included RCTs involve the use of Epidiolex, and the findings should not be extrapolated to other preparations. The effects of CBD and other cannabis-based products on other outcomes are less clear, and our understanding of the potential benefits and harms in this population will be refined as data from ongoing studies become available. In particular, there is currently limited clinical information about the benefits and harms of cannabis-based products with high THC content.
The use of clobazam by children with DRE is common; in the included RCTs, up to 66% of children received clobazam in addition to CBD. 12, [28] [29] [30] Cannabidiol is an inhibitor of multiple CYP enzymes, notably CYP34A and CYP2C19, which are involved in the clearance of N-desmethylclobazam, the active metabolite of clobazam. 48 As such, inhibition of CYP enzymes by CBD has the potential to increase the serum concentration of clobazam and other AEDs. Elevated clobazam and N-desmethylclobazam levels have been reported among children with DRE who received both CBD and clobazam, 28, 42 which may have implications for both efficacy and safety. A higher rate of seizure freedom has been reported among children who received concomitant CBD and clobazam than either agent alone, 35 and increased somnolence has been noted among children who received both CBD and clobazam compared to those who received clobazam alone. 12 Others have noted that the adverse events observed among children taking both CBD and clobazam are similar to those seen at high clobazam doses, and that reduction of clobazam may be sufficient to alleviate adverse events.
42
A previous systematic review 49 involving children and adults with epilepsy similarly found that CBD was more effective than placebo at improving treatment response and reducing seizure frequency. In contrast with our findings, Stockings and colleagues 49 reported that CBD increased seizure freedom and improved quality of life. These apparent discrepancies are likely related to methodological differences. In their analysis of seizure freedom, Stockings and colleagues 49 combined estimates of freedom from all seizures with freedom from drop or convulsive seizures, whereas our assessment included only studies that reported freedom from all seizures. Although we found no statistically significant difference between groups, this finding was based on one RCT, and the publication of additional studies assessing freedom from all seizures will help to clarify whether there is a beneficial effect of CBD. Similarly, methodological differences may be responsible for the discrepant findings in quality of life between the Stockings 49 review and our analysis. Stockings and colleagues 49 assessed quality of life by use of the Caregiver Global Impression of Change score, which assesses whether, in the caregiver's opinion, the child's overall condition has improved. In our review, we used the Quality of Life in Childhood Epilepsy score, which has been validated for use by parents of children with DRE to assess healthrelated quality of life and is sensitive to seizure severity and medication effects. 50 Parents of children with DRE have reported that "unacceptable AED side effects" and the belief that cannabisbased products are "more natural" and more effective are motivating factors for their willingness to enroll their child in a trial of cannabinoids for epilepsy. 39 However, a previous review 49 reported an increased risk of adverse events and serious adverse events among children and adults who received CBD compared with placebo, and we found that the risk of diarrhea was significantly higher among children who received CBD. As such, the decision to administer CBD or other cannabis-based products should be based on shared decision making between parents and health care providers, with consideration of both the potential benefits and harms.
| Strengths and limitations
The protocol for this review was published a priori, 19 and we followed rigorous systematic review methodology. To ensure the relevance of our findings to decision making, two family members of children with epilepsy and a pediatric neurologist were collaborators on this project. Because there is little certainty in the evidence base, and because there are a number of ongoing studies, this review will be updated at 6-month intervals to include new evidence as it becomes available, and updates will be posted online at cannabisandepilepsy.blogspot.com. Several limitations should be considered. First, most included NRSs were at high risk of at least one important source of bias (eg, selection, performance, ascertainment) and the certainty of the evidence from such studies is very low owing to the high risk of bias. Although NRSs may be important sources of evidence for understanding of realworld effectiveness and informing health care decision making, 51 such biases affect the ability to evaluate effectiveness and safety. However, the findings were generally consistent between the included RCTs and NRSs, although the magnitude of treatment benefit was often greater among NRSs. This was expected, given the high rate of placebo response in pediatric epilepsy studies 52 combined with the use of subjective outcomes and a lack of blinding. In the placebo arm of the included RCTs, the percentage reduction in seizures was between 9% and 18.5% and the responder rate was 21% (Appendix S10, Appendix S12), which is consistent with the reported placebo responder rate of 19.7% from a pooled analysis of double-blind RCTs involving children with refractory epilepsy. 52 Given this high responder rate among participants who received placebo in the RCTs, in the NRS involving only one treatment arm, it is difficult to separate the effect of the cannabis-based intervention from a possible placebo response. Second, there was considerable heterogeneity in terms of the interventions and duration of treatment. All included RCTs involved Epidiolex, a pharmaceutical-grade CBD preparation recently approved by the US Food and Drug Administration for Dravet and Lennox-Gastaut syndromes. 16 Whether the observed effects extend to other cannabis-based products is unknown. Similarly, almost half of the NRS involved Epidiolex, whereas others involved multiple cannabis-based products, which were often poorly described. All included RCTs had relatively short treatment durations (up to 14 weeks); thus, it is not clear whether the observed effects are sustained over a longer duration. Although the NRSs involved up to 57 months of treatment, the available data did not allow for an assessment of maintenance of effect. Third, the effects of cannabis-based products on individual epilepsy syndromes are currently limited and are primarily related to Dravet 12, 28 and Lennox-Gastaut syndromes. 29, 30 Evidence from NRSs suggests that CBD may also be effective in TSC, 44 Sturge-Weber syndrome, 32 and febrile infection-related epilepsy 43 ; however, these studies were based on few participants and were subject to important biases. Fourth, in most studies, cannabis-based products were added to an established regimen of antiepileptic therapies, including concomitant AEDs, in children with DRE. As such, whether cannabis-based products are effective as first-line therapy for newly diagnosed epilepsy is unknown. Additionally, although some studies required that the type and dose of AEDs be held constant, AED treatments were more fluid in other studies, particularly retrospective studies, with additional interventions added or removed during the treatment period, potentially confounding the results. 35 Interactions between some AEDs (eg, clobazam) and CBD have been suggested, 42 although this has yet to be investigated in well-controlled long-term studies. Fifth, although seizure freedom, the primary outcome of this review, was identified by family members and a practicing neurologist as being of utmost importance, it may not be an attainable outcome for children with DRE. In this population, a reduced burden of seizures and the avoidance of status epilepticus may be more realistic goals, with a 50% reduction in seizures being a desirable outcome. As such, it is not unsurprising that a small proportion of children with Dravet syndrome experienced seizure freedom with CBD treatment. 12 However, the observed reduction in seizure frequency and increased number of children with Dravet or Lennox-Gastaut syndrome with ≥50% reduction in seizures is a clinically important finding.
Evidence from recent high-quality RCTs suggests that CBD is effective in reducing seizure burden among children with drug-resistant Dravet and Lennox-Gastaut syndromes (moderate certainty); however, few children experienced complete seizure freedom. Although the evidence is currently limited, children with other DRE syndromes may experience similar benefit. These findings should not be extended to all cannabis-based products, especially those of unknown composition.
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